Blog
What is Type 1.5 Diabetes?
Understanding Latent Autoimmune Diabetes in Adults (LADA)
Tatiana Dorenko, DNP, APRN, FNP-BC
Physician Reviewed
Diabetes is usually described as either Type 1 or Type 2, but that framework is incomplete. There is a third, often overlooked form called Latent Autoimmune Diabetes in Adults (LADA), sometimes referred to as "Type 1.5 diabetes." The term is informal, but it reflects a real clinical problem: autoimmune diabetes that develops slowly in adulthood and is frequently mistaken for Type 2 diabetes.
Understanding LADA matters because misclassification can delay appropriate treatment and lead to years of suboptimal glycemic control.
What is LADA?
Latent Autoimmune Diabetes in Adults is a form of autoimmune diabetes in which the immune system gradually destroys insulin-producing beta cells in the pancreas. Like Type 1 diabetes, the underlying mechanism is autoimmune. Unlike classic Type 1 diabetes, the progression is slow, often unfolding over months to years rather than suddenly.
Because insulin production does not disappear immediately, people with LADA may initially maintain partial glycemic control without insulin. This is one reason the condition is frequently misdiagnosed as Type 2 diabetes at onset. According to the Mayo Clinic, LADA is often initially mistaken for Type 2 diabetes due to its adult onset and gradual progression, despite being autoimmune in nature.
Why It's Often Missed
The biggest clinical challenge with LADA is that early presentation overlaps heavily with Type 2 diabetes. Adults present with elevated glucose levels, and many clinicians reasonably start with lifestyle modification and oral antihyperglycemic agents.
However, underlying physiology is different. In Type 2 diabetes, insulin resistance is the primary driver. In LADA, insulin resistance may or may not be present, but progressive beta-cell failure is inevitable.
Several features can raise suspicion that the diagnosis may not be straightforward:
Lean body habitus or absence of metabolic syndrome features
Personal or family history of autoimmune disease
Rapid decline in glycemic control despite oral agents
Early need for insulin compared with typical Type 2 diabetes progression
Unintentional weight loss or poor response to standard therapy
This pattern of "treatment failure" is often the first real clue that the diagnosis needs to be reconsidered.
What Causes LADA?
LADA is caused by autoimmune destruction of pancreatic beta cells. The immune system mistakenly targets these cells, gradually reducing endogenous insulin production.
Research suggests a genetic predisposition combined with enviornmental triggers, though the exact initiating factors remain unclear. Like other autoimmune conditions, LADA is more common in people who have or develop additional autoimmune diseases such as autoimmune thyroid disease or celiac disease.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) classifies LADA within the spectrum of autoimmune diabetes, emphasizing its immunologic basis rather than metabolic insulin resistance.
Symptoms and Clinical Presentation
The symptoms of LADA overlap significantly with other forms of diabetes, which contributes to delayed recognition. Common symptoms include increased thirst, frequent urination, fatigue, blurred vision, and unexplained weight loss.
What differentiates LADA is not the symptom profile itself, but the trajectory. Symptoms tend to worsen gradually, and glucose control deteriorates despite conventional therapy.
In many cases, patients initially feel stable on oral medications, only to experience progressive loss of control over time as beta-cell function declines.
How LADA is Diagnosed
Definitive diagnosis requires looking beyond routine glucose testing. While hyperglycemia is the entry point, confirmation depends on identifying autoimmune activity and measuring insulin production capacity.
The most important diagnostic tools include:
Autoantibody testing, particularly GAD65 antibodies, which are commonly positive in LADA
C-peptide testing to assess endogenous insulin production
Glycemic markers such as HbA1c to evaluate chronic control
The presence of islet antibodies strongly supports autoimmune diabetes rather than Type 2 diabetes. C-peptide levels help determine whether insulin production is preserved or declining.
Clinically, the diagnosis is often made only after a patient labeled as having Type 2 diabetes shows an unexpected and rapid need for insulin therapy.
Treatment Approach
Treatment depends on the stage of beta-cell decline at diagnosis.
In early LADA, some patients may respond temporarily to non-insulin therapies. However, this phase is typically limited. Because the underlying process is progressive autoimmune destruction, most individuals eventually require insulin therapy.
There is ongoing discussion in endocrinology about whether earlier insulin initiation may help preserve remaining beta-cell function. While evidence is still evolving, many specialists advocate early transition to insulin when LADA is suspected rather than prolonged escalation of oral agents that do not address the underlying pathology.
Importantly, treatment is not only about glucose lowering. It is about aligning therapy with physiology before prolonged hyperglycemia causes downstream complications.
Why Correct Diagnosis Matters
Mislabeling LADA as Type 2 diabetes is not a benign error. It changes the trajectory of care.
When autoimmune diabetes is not recognized, patients may:
Remain on ineffective therapies longer than appropriate
Experience prolonged periods of hyperglyemia
Delay insulin initiation
Accumulate preventable metabolic stress and complications
Correct identification allows for earlier insulin planning, more accurate patient education, and more realistic expectations about disease progression.
LADA in the Bigger Picture of Diabetes Care
LADA highlights a broader issue in diabetes classification: real patients do not always fit neatly into textbook categories. Adult-onset autoimmune diabetes sits in a diagnostic gray zone that requires clinical suspicion, not just algorithmic labeling.
Greater awareness among clinicians improves early detection. Greater awareness among patients helps prompt appropriate questioning when the clinical course does not match expectations.
Bottom Line
Latent Autoimmune Diabetes in Adults is a slow progressive autoimmune form of diabetes that often appears similar to Type 2 diabetes at diagnosis but behaves differently over time. The key distinction is not how it starts, but how it progresses: gradual loss of insulin production driven by autoimmune destruction.
Recognizing this pattern early allows for more appropriate treatment decisions and avoids years of ineffective management.
Covenant Metabolic Specialists has upcoming diabetes studies focused on advancing understanding and treatment of metabolic and autoimmune diabetes.
Medical Advice Disclaimer
The content on CMS’s website (including, without limitation, any testimonials) is for general informational purposes only. It is not intended to diagnose or treat any condition, illness, or disease. All content from this site or connected social media channels is not intended to be used for medical diagnosis or treatment. Please consult a licensed medical professional for medical advice. CMS does not guarantee the accuracy, completeness, or timeliness of any information presented on this website.
